Advanced Oncotherapy, the developer of a next-generation proton therapy system for cancer treatment, has appointed Moataz Karmalawy as chief commercial officer and president of the US division.
Karmalawy previously served as general manager of the Worldwide Particle Therapy Business for Varian Medical Systems, the world’s largest manufacturer of radiotherapy equipment for 12 years. Karmalawy also worked at Philips Medical Systems for ten years where he served in several senior executive roles.
Chief executive officer of Advanced Oncotherapy, Nicolas Sérandour said: ‘Bringing someone of Mr Karmalawy’s calibre and experience on board is a testament to the advantages of our next-generation proton beam technology and to the opportunity that presents itself as we move towards commercialisation of the LIGHT system.
‘With the global capacity to treat patients with proton therapy of only 50,000 patients a year, and roughly 350,000 patients diagnosed with cancer each year in the UK alone, it is clear that there is a desperate need for the roll-out of a technology that can bring the benefits of proton beam therapy to millions of patients worldwide.’
Karmalawy added: ‘The global capacity to treat patients with proton therapy has been disappointingly low due to the high cost of traditional proton therapy technologies. As a result, only 1% of patients eligible for radiotherapy are being treated with proton therapy.
‘Advanced Oncotherapy’s technology will make this treatment more affordable and accessible to cancer patients worldwide and the LIGHT system has a number of technical advantages to existing technology that will deliver better patient outcomes and offer an accuracy and adjustability beyond legacy technologies.’